Comparison · NCT01466036-sae
Metastatic or Unresectable PNET vs Metastatic or Unresectable Carcinoid: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Metastatic or Unresectable PNET vs Metastatic or Unresectable Carcinoid: serious adverse events. Trial comparisons, record NCT01466036-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01466036-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.75 | 0.531 | 0.888 | wilson | |
| Risk in group 2 | 0.585 | 0.434 | 0.722 | wilson | |
| Risk difference, group 1 minus group 2 | 0.165 | -0.0935 | 0.37 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.28 | 0.893 | 1.84 | log | |
| Odds ratio, group 1 over group 2 | 2.13 | 0.648 | 6.97 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Metastatic or Unresectable PNET than on Metastatic or Unresectable Carcinoid | 6.07 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Metastatic or Unresectable PNET | patients were stratified by primary tumor site but received the same treatment. This cohort had pancreatic neuroendocrine tumors.~Cabozantinib: 60 mg QD orally in cycles of 28 days | 15 | 20 | EG000 |
| Group 2 | Metastatic or Unresectable Carcinoid | Patients were stratified by primary tumor site but received the same treatment. This cohort had advanced or metastatic carcinoid tumor.~Cabozantinib: 60 mg QD orally in cycles of 28 days | 24 | 41 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Participants were followed for AEs and SAEs starting from the first dose of study treatment, throughout the study, and through 30 days from the last study treatment. Median treatment duration was 8 cycles for the Carcinoid cohort and 12.5 cycles for the PNET cohort. Patients were followed for AEs during the time on treatment plus 30 days (median of 9.6 months). Participants were followed for All-Cause Mortality for longer (median 89.1 months).
Source ClinicalTrials.gov
Trial
- Title
- Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
- NCT number
- NCT01466036
- Phases
- PHASE2
- Conditions
- Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
- Interventions
- Cabozantinib
- Lead sponsor
- Dana-Farber Cancer Institute
- Results first posted
- 2023-07-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01466036?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01466036-sae